CDI-45205 / Cocrystal Pharma - LARVOL DELTA

Cocrystal Pharma Inc's CDI-45205 Shows Promising Results Against SARS-CoV-2 And Its Variants (BioPharma Journal) - "Cocrystal’s third-party lab evaluated CDI-45205 and its analogs antiviral activity in in-vitro studies against the UK variant (B.1.1.7), SARS-CoV-2 (Wuhan strain), and the South African variant (B.1.351)....CDI-45205 and its analogs demonstrated improved antiviral activity against the coronavirus variants. It successfully acted against the Wuhan strain. The company included PF-remdesivir...and another SARS-CoV-2 3CL protease inhibitor – PF-00835231, in the preclinical trial as the comparators. CDI-45205 showed improved antiviral activity against the coronavirus variant found in the UK with 1.9 uM EC50 compared to remdesivir’s 0.6 uM EC50 and PF-00835231’s >100 uM EC50. It is also effective against the South African variant with 2.5 uM EC50."

Preclinical • Infectious Disease • Novel Coronavirus Disease

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. (PubMed, Curr Opin Virol) - "Here we review first-generation SARS-CoV-2 3CLpro inhibitors PF-07304814, GC-376, and CDI-45205 that are being delivered either by injection or inhalation due to their low intrinsic oral bioavailability. In addition, PF-07321332 is now emerging as a promising second-generation clinical candidate for oral delivery. A key challenge to the development of novel 3CLpro inhibitors is the poor understanding of the predictive value of in vitro potency toward clinical efficacy, an issue complicated by the involvement of host proteases in virus entry. Further preclinical and clinical validation will be key to establishing 3CLpro inhibitors as a bona fide class for future SARS-CoV-2 therapeutics for both hospitalized and outpatient populations."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases